

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Director/PDMR Shareholding

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 02 May 2017 it purchased 1,329 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at a price of 4.9p per Ordinary Share (the "First Purchase"). The Company has also received notification that on 03 May 2017 Vulpes purchased a further 240 Ordinary Shares at a price of 4.85p per Ordinary Share (the "Second Purchase") (together with the First Purchase, "the Purchases"). Following the Purchases Vulpes has a total direct and indirect interest in 54,145,284 equivalent to 18.38% of Proteome Sciences' total issued share capital.

The Company would also like to announce that by virtue of Martin Diggle being a Director of both Vulpes and the Company, he now has an interest in 54,145,284 Ordinary Shares of the Company representing 18.38% of the issued share capital of the Company.

1. Details of the person discharging managerial responsibilities / person closely associated
 - a) Name Vulpes Life Sciences Fund
2. Reason for the Notification
 - a) Position/status PCA of Martin Diggle (NED)
 - b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name Proteome Sciences plc
 - b) LEI n/a
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
 - a) Description of the Financial instrument, type of instrument Ordinary Shares of 1p each
Identification code GB0003104196
 - b) Nature of the transaction Purchase
 - c) Price(s) and volume(s) 1,329 Ordinary Shares at 4.9p per Ordinary Shares
240 Ordinary Shares at 4.85p per Ordinary Shares
 - d) Aggregated information:
 - Aggregated volume 1,569 Ordinary Shares of 1p each purchased at a volume weighted average price of 4.89p per Ordinary Share
 - Price
 - e) Date of the transaction 2 May 2017 (First Purchase), 3 May 2017 (Second Purchase)
 - f) Place of the transaction London Stock Exchange, AIM Market (XLON)

For further information:

Proteome Sciences plc

Dr Jeremy Haigh, Chief Executive Officer
Dr Ian Pike, Chief Scientific Officer

Tel: +44 (0)1932 865065

Geoff Ellis, Finance Director

finnCap Limited (Nominated Adviser/Broker)

Geoff Nash/James Thompson
Tony Quirke (broking)

Tel: +44 (0)20 7220 0500

IFC Advisory (Financial PR and IR)

Tim Metcalfe/Graham Herring/Miles Nolan

Tel: +44 (0)20 3053 8671

Notes for editors:

Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant[®], TMTcalibrator[™]) and for the discovery, validation and assay development of protein biomarkers. The company has its headquarters in Cobham, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services[™] division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.

Proteome Sciences has patented a number of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.